"One belt, one road" emerging medicine market: opportunities and challenges

As we all know, China has become the second largest biomedical market in the world However, in recent years, under the influence of a series of policies such as consistency evaluation and volume procurement, the domestic pharmaceutical market environment has changed dramatically, and international development has become an important starting point for promoting the structural adjustment of China's pharmaceutical industry and the transformation and upgrading of pharmaceutical enterprises In the process of internationalization, on the one hand, the growth rate of the pharmaceutical market in developed countries and regions such as Europe and the United States is slowing down, the technical regulations are strict, and it is more difficult to enter; on the other hand, the potential of emerging markets is huge According to statistics, 80% of the growth of drug sales in the future comes from emerging markets By 2022, emerging markets will account for 56% of the global drug market sales, compared with 49% in 2012 The "one belt, one road" initiative provides a historical opportunity for international cooperation between domestic enterprises and emerging market countries One belt, one road, new China pharmaceutical market Symposium and the signing ceremony of the strategic cooperation framework agreement of Clarivate Analytics of China Medical and health products import and export association was held in Beijing in October 29th China's one belt, one road one belt, one road researcher, Wu Fang, deputy director of the Institute of economic and trade cooperation, said that as of the end of August 2019, 136 countries and 30 international organizations signed 195 cooperation documents with China China China one belt, one road, the total trade volume of goods increased from US $1 trillion and 40 billion in 2013 to US $1 trillion and 270 billion in 2018, and the share of China's total trade in goods increased from 25% to 27.4% One belt, one road, is China's health insurance association The Chinese Medical Insurance Association has introduced the huge population base, huge market capacity, low drug self-sufficiency rate and high dependence on imports The escalation of the "one belt" free trade agreement has laid a solid foundation for domestic pharmaceutical companies to launch medical and health cooperation in emerging markets Ceng Yali, consultant of life science and pharmaceutical solutions, based on the emerging market analysis provided by the coreway global strategic team, Cortellis's global drug administration and regulation intelligence database (CRI), clinical trial database (CTI), incidence rate and Morbidity Database (IPD), and comprehensive intelligence database of generic drugs, API and intermediates (Newport) Premium), analyzed the general situation and trend of major emerging pharmaceutical markets in the Middle East and North Africa (MENA), sub Saharan Africa (SSA), Latin America (LATAM), and Russia In addition, Ms Zeng Yali also introduced the key points for success in the MENA Market: 1 Whether generic or patented drugs, brand effect should be established; 2 Social media and mobile applications should be used to provide patients with helpful health tools; 3 Community awareness of health problems and diseases should be improved; 4 Skilled biopharmaceutical workers should be recruited and trained (for example, providing real products 5 Provide regional training programs and scholarships for global conferences to help doctors in the Middle East and North Africa keep up with the pace of medical development; 6 Conduct local clinical trials of approved drugs to improve doctors' awareness; Opportunities and challenges coexist, the regulatory diversity of SSA pharmaceutical market and drug listing are facing many difficulties: 1 Delays in marketing and approval of clinical trials Market access approval in some low and middle-income countries (LMICs) will be delayed For medical products, the delay may be 4-7 years 2 The SSA consists of 48 countries There is a big difference in demand between limits, but it is difficult for pharmaceutical companies to develop the same drugs for different countries, and the approval mechanism between countries is lack of integration 3 Meeting needs is challenging The challenges in this regard are mainly reflected in the differences in the maturity and consistency of regulators, and the huge gaps in market size, growth trajectory, macroeconomic pattern, legal structure and political complexity among countries 4 Different LMICs may have different requirements for stability SSA covers three climate zones: II, IVA and IVB, while pharmaceutical companies may only realize the first climate zone If they want to meet different needs, they need to carry out stability tests again, but there is no predictable stability test requirements, and the time to market is delayed at least six months Argentina's pharmaceutical market: Argentina is the fourth largest pharmaceutical market of LATAM After years of strong expansion, the growth of pharmaceutical sales has slowed down, resulting in a sharp slowdown in the economy, a decrease in real income and sustained inflation In this context, pharmaceutical companies face two challenges: on the one hand, to provide affordable and effective treatment for consumers, on the other hand, to achieve revenue and market goals Brazilian pharmaceutical market: Brazil is the sixth largest market in the world, despite having a national healthcare project, sistema Unicode Saude, however, 25% of the population choose to buy private insurance to obtain second-line and third-line medical services, which leads to a large number of patients can not get super basic level of care, making potential subjects in the early stage of treatment to a large extent, which not only promotes the participation of clinical trials, but also promotes the sustainability of patients In addition, there is fierce competition for generic drugs in Brazil, but increasing attention to early clinical trials is good news for innovative research Mexican pharmaceutical market: Mexico is the 11th largest pharmaceutical market in the world, with a market size of more than 13.2 billion US dollars With a population of 120 million and a stable economic situation, the GDP is expected to grow by 2.1% With a wide range of medical needs, especially those related to chronic diseases such as cardiovascular disease, diabetes and cancer, many multinational companies still regard Mexico as an "emerging market".